NovoCure's TTFields Therapy Extends Survival in Advanced Pancreatic Cancer

NovoCure Ltd. has made a major breakthrough in pancreatic cancer treatment using its Tumor Treating Fields (TTFields) technology. Recent trial results show the therapy significantly extends survival rates for patients with advanced disease. The news has already boosted the company's stock by 15% on NASDAQ, with analysts raising price targets in response.

The PANOVA-3 clinical trial, conducted between 2020 and 2024, tested TTFields alongside chemotherapy in patients with stage IV pancreatic cancer. Leading centres like Berlin's Charité recruited participants for the study. Interim findings revealed that those receiving TTFields achieved a median progression-free survival of 12.5 months, compared to 8.7 months in the control group. Overall survival also improved, with treated patients living 14.3 months on average versus 11.6 months for others.

TTFields, already approved for glioblastoma, could now transform pancreatic cancer care. Regulatory approvals in Europe may speed up NovoCure's expansion in the region, a key market for the technology. The company's 2026 guidance predicts 10–15% revenue growth, but analysts suggest this could double if TTFields gains approval for new cancer types. Financially, NovoCure remains strong, reporting $150 million in revenue last quarter and holding $400 million in cash. This reserve ensures operations can continue for at least 24 months without additional funding. The technology's potential extends beyond pancreatic cancer, with possible applications in other solid tumours.

The PANOVA-3 results mark a turning point for NovoCure, reinforcing TTFields as a promising option for hard-to-treat cancers. With regulatory momentum in Europe and a solid financial position, the company is well-placed to expand its reach. Further approvals could unlock broader use of the technology in oncology.